XML 30 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
RESTRUCTURING
 12 Months Ended
Mar. 30, 2024
Restructuring and Related Activities [Abstract]  
RESTRUCTURING RESTRUCTURING
On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.
Operational Excellence Program

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company expects to incur aggregate charges between $85 million and $95 million by the end of fiscal 2025 under the program. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During fiscal 2024, 2023 and 2022, the Company incurred $9.8 million, $11.5 million and $28.7 million of restructuring and restructuring related costs under this program, respectively. Total cumulative charges under this program are $77.0 million as of March 30, 2024.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities.

The following table summarizes the activity for restructuring reserves related to portfolio rationalization initiatives, the 2020 Program and prior programs for the fiscal years ended March 30, 2024, April 1, 2023 and April 2, 2022, substantially all of which relates to employee severance and other employee costs:
(In thousands)Portfolio Rationalization2020 ProgramPrior ProgramsTotal
Balance at April 3, 2021
$— $575 $437 $1,012 
Costs incurred, net of reversals— 4,202 28 4,230 
Payments— (2,317)(120)(2,437)
Balance at April 2, 2022$— $2,460 $345 $2,805 
Costs incurred, net of reversals— 576 81 657 
Payments— (1,226)(86)(1,312)
Balance at April 1, 2023$— $1,810 $340 $2,150 
Costs incurred, net of reversals13,915 450 (276)14,089 
Payments(2,606)(1,775)(64)(4,445)
Balance at March 30, 202411,309 485 — 11,794 

The following presents the restructuring costs by line item during fiscal 2024, 2023 and 2022 within our accompanying consolidated statements of income and comprehensive income:
(In thousands) 202420232022
Cost of goods sold$11,286 $(215)$2,236 
Research and development456 — 105 
Selling, general and administrative expenses2,347 872 1,889 
Total$14,089 $657 $4,230 

As of March 30, 2024, the Company had a restructuring liability of $11.8 million, all of which is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $9.5 million, $10.9 million and $24.6 million in fiscal 2024, 2023 and 2022, respectively, that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.
The following presents the restructuring related costs by line item during fiscal 2024, 2023 and 2022 within our accompanying consolidated statements of income and comprehensive income:
(In thousands) 202420232022
Cost of goods sold$5,734 $7,991 $17,832 
Research and development1,750 1,050 714 
Selling, general and administrative expenses2,015 1,851 6,048 
Total$9,499 $10,892 $24,594 

The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costs
(In thousands) 202420232022
Plasma$1,015 $(48)$2,492 
Blood Center5,606 — (18)
Hospital3,863 165 (93)
Corporate3,605 540 1,849 
Total$14,089 $657 $4,230 
Restructuring related costs
(In thousands) 202420232022
Plasma$1,050 $1,385 $7,906 
Blood Center286 75 556 
Hospital408 546 379 
Corporate7,755 8,886 15,753 
Total$9,499 $10,892 $24,594 
Total restructuring and restructuring related costs$23,588 $11,549 $28,824